Biotech Investors & VC Firms in United Kingdom
294 firms in this list, with a median first check of $500K. 62 of them lead rounds. Generated from verified public data and updated continuously.
Forepont Capital Partners
New YorkPre-Seed–Late Stage
26 people
Essex Woodlands Healthcare Partners
New YorkGrowth–Late Stage$20M – $80M
18 people
J2 Ventures
BostonPre-Seed–Series A
19 people
Blue Horizon Corporation
ZurichPre-Seed–Late Stage
Eurazeo
ParisSeries A–Late Stage
12 people
The Yield Lab Europe
DublinPre-Seed–Series A$108K – $2.2M
13 people
Galion.exe
Seed$275K – $2.8M
16 people
Astellas Venture Management LLC
South San FranciscoSeed–Growth$200K – $5M
10 people
Epidarex Capital
BethesdaPre-Seed–Series A$2.5M – $6.3M
12 people
Lunar Ventures
BerlinPre-Seed–Seed$500K – $2M
16 people
Quantonation
ParisPre-Seed–Series B
13 people
SAV (Scale Asia Ventures)
Palo AltoSeed–Series B
12 people
Dimension Capital
San FranciscoSeed–Late Stage$1M – $10M
14 people
Keensight Capital
ParisGrowth–Late Stage$10M – $800M
5 people
Quan Capital
ShanghaiSeed–Late Stage
16 people
Onsight Ventures
InnsbruckPre-Seed–Series A$216K – $2.2M
14 people
BIOSPRING PARTNERS
New YorkGrowth–Late Stage
22 people
Noetic
TorontoSeed–Series A
13 people
ACT Venture Capital
DublinSeed–Growth$1.1M – $16.2M
11 people
New Mountain Capital
New YorkGrowth–Late Stage
6 people
JK&B Capital
ChicagoPre-Seed–Late Stage
9 people
New Science Ventures
GreenwichSeed–Late Stage$2M – $8M
7 people
Senovo
MunichSeed–Late Stage$1.1M – $5.4M
7 people
REMUS Capital
BostonPre-Seed–Series B$25K – $20M
9 people
Related lists
Investors & VC Firms in North America (14143)Investors & VC Firms in United States (13281)Investors & VC Firms in Europe (5575)Crypto & Web3 Investors & VC Firms (4830)Investors & VC Firms in Global (4158)SaaS Investors & VC Firms (3865)AI & Machine Learning Investors & VC Firms (3769)Fintech Investors & VC Firms (3726)Investors & VC Firms in Asia-Pacific (3574)Healthtech Investors & VC Firms (3415)
Data sourced from public filings and firms' own websites — see our methodology.






























































































